Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
about
Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trialSystematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.Epothilones in the treatment of ovarian cancer.Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances.
P2860
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Optimizing ixabepilone treatme ...... d or metastatic breast cancer.
@ast
Optimizing ixabepilone treatme ...... d or metastatic breast cancer.
@en
Optimizing ixabepilone treatme ...... d or metastatic breast cancer.
@nl
type
label
Optimizing ixabepilone treatme ...... d or metastatic breast cancer.
@ast
Optimizing ixabepilone treatme ...... d or metastatic breast cancer.
@en
Optimizing ixabepilone treatme ...... d or metastatic breast cancer.
@nl
prefLabel
Optimizing ixabepilone treatme ...... d or metastatic breast cancer.
@ast
Optimizing ixabepilone treatme ...... d or metastatic breast cancer.
@en
Optimizing ixabepilone treatme ...... d or metastatic breast cancer.
@nl
P2860
P921
P1476
Optimizing ixabepilone treatme ...... d or metastatic breast cancer.
@en
P2093
Nancy Egerton
P2860
P2888
P304
P356
10.1007/S00280-010-1467-X
P577
2010-10-01T00:00:00Z
2010-11-01T00:00:00Z
P5875
P6179
1035742930